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ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice
The widespread use of fetal cell-free DNA (cfDNA)-based techniques to screen for trisomy 21 and other aneuploidies has expanded greatly the range of prenatal tests available over the last few years. cfDNA tests are being incorporated rapidly into prenatal care, thus changing the traditional approach to prenatal screening and diagnosis. However, although cfDNA techniques are highly efficient, their role and performance must be considered alongside and combined with other screening modalities. The role of prenatal ultrasound, in particular, needs to be reaffirmed as cfDNA testing becomes more widely available.
It is important to emphasize that the main goal of prenatal screening is to provide accurate information that will facilitate the delivery of optimized antenatal care, with the best possible outcome for both mother and fetus. Women should be informed about the prevalence and the clinical manifestation of the disease of interest and about prenatal screening performance (detection rate, false-positive rate, positive predictive value in the general population, failure rate) by appropriately trained health professionals, allowing them to make an informed decision. It is the parent's choice to undergo such procedures, and their wishes should be determined and respected.
This consensus statement constitutes a revised and updated version of the previously published ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice 1 ; updates will be produced on a regular basis.
• All women should be offered a first-trimester ultrasound scan according to ISUOG guidelines 2 , regardless of their intention to undergo cfDNA testing. An invasive test might be discussed in light of the recently reported reduction in the risk of invasive procedures 3, 4 , as well as the increase in cytogenetic resolution provided by microarray techniques. However, the cost of this option is not usually covered by most national insurance policies and it should not be recommended beyond the context of clinical trials and until sufficient peer-reviewed data and validation studies have been published.
• cfDNA test results should always be interpreted and explained individually in relation to the a-priori risk and the fetal fraction.
• In the presence of a fetal structural anomaly, the indications for fetal karyotyping and/or microarray testing should not be modified by a previously normal cfDNA test result.
• In the case of a failed cfDNA test, the patient should be informed about the increased risk of anomalies as well as alternative screening and testing strategies.
• cfDNA testing is not diagnostic, and confirmatory invasive testing is required in the presence of an abnormal result. Whenever there is discordance between an abnormal cfDNA test result and a normal ultrasound examination, amniocentesis rather than chorionic villus sampling should be performed.
• Accuracy of cfDNA testing in twin pregnancies should be investigated further.
• Variations in cfDNA test performance by different providers should be investigated further.
• It is becoming technically feasible to test non-invasively, not only for trisomies but also for other genetic syndromes. Both healthcare providers and women should be clearly aware of the tests being performed and of their performance, as having multiple tests increases the overall false-positive rate and failure rate. The detection rate for microdeletions has yet to be established and most national guidelines currently do not support testing for microdeletions on cfDNA. Screening for microdeletions also raises complex issues regarding pretest and post-test counseling.
• Prospective, publicly funded studies assessing the cost-effectiveness of various screening strategies should be performed as a matter of urgency. 
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